These can be useful parameters to establish recent reticulocyte stimulation of reticulocytes in response to rHuEpo
usage contrasting with results seen in normal physiologic RBC production.
In this context, recently, expression of rHuEpo
was discontinued after six weeks of treatment; Hb was 12.
Kirin began marketing a rHuEPO
preparation, brand name ESPO(R) INJECTION, for the treatment of renal anemia in 1990, which has contributed greatly to the care of dialysis patients with renal anemia.
The general approach to detecting blood doping is to use indirect methods for screening and more specific methods for firm evidence of exogenous rHuEPO
Very little is known about the time course of urinary rHuEPO
after its administration.
Most of the exercise training studies in people with ESRD occurred before the use of rhuEPO
Complications of rHuEpo
use have included hypertension, clotted hemodialysis access, and, less commonly, seizures (Henna et al.
In California, Georgia, and Michigan, rHUEPO
accounted for 9.
Barany, "Anaemia, rHuEPO
resistance, and cardiovascular disease in end-stage renal failure: links to inflammation and oxidative stress," Nephrology Dialysis Transplantation, vol.
Results of the first human trials of rHuEPO
were published in 1986-1987 (Eschbach, Egrie, Downing, Browne, & Adamson, 1987; Winearls et al.
In recent years, studies have focused on the use of rHuEpo
for other indications.